OTCMKTS:CLPBY Coloplast A/S (CLPBY) Stock Price, News & Analysis $7.46 -0.03 (-0.40%) As of 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsInsider TradesNews and TrendsShort Interest About Coloplast A/S Stock (OTCMKTS:CLPBY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coloplast A/S alerts:Sign Up Key Stats Today's Range$7.45▼$7.5450-Day Range$6.18▼$7.9252-Week Range$5.64▼$9.29Volume53,749 shsAverage Volume322,615 shsMarket Capitalization$16.81 billionP/E Ratio18.67Dividend Yield1.07%Price TargetN/AConsensus RatingModerate Buy Company Overview Coloplast A/S is a Danish medical device company that develops and markets products and services for people with intimate health care needs. Its main business areas include ostomy care, continence care, wound and skin care, and urology care. Its products include ostomy bags and accessories, catheters and other continence products, wound dressings, and devices used in urological procedures. Coloplast also provides voice and respiratory care products, including solutions for people who have had a laryngectomy. Founded in Denmark in 1957, Coloplast serves customers in markets around the world. The company was established after nurse Elise Sørensen helped develop an ostomy bag for her sister, in collaboration with entrepreneur Aage Louis-Hansen.AI Generated. May Contain Errors. Read More Coloplast A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreCLPBY MarketRank™: 3.862068965515 of 5 starsColoplast A/S scored higher than 77% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingModerate Buy Consensus RatingColoplast A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 2 strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageColoplast A/S has only been the subject of 1 research reports in the past 90 days.Read more about Coloplast A/S's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth10.81% Earnings GrowthEarnings for Coloplast A/S are expected to grow by 10.81% in the coming year, from $0.37 to $0.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coloplast A/S is 18.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.70.Price to Earnings Ratio vs. SectorThe P/E ratio of Coloplast A/S is 18.67, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.43.Price to Earnings Growth RatioColoplast A/S has a PEG Ratio of 3.54. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioColoplast A/S has a P/B Ratio of 7.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Coloplast A/S has been sold short.Short Interest Ratio / Days to CoverColoplast A/S has a short interest ratio ("days to cover") of 0.51, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coloplast A/S has recently decreased by 89.72%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldColoplast A/S pays a meaningful dividend of 1.13%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthColoplast A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Coloplast A/S is 38.10%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Coloplast A/S will have a dividend payout ratio of 19.51% next year. This indicates that Coloplast A/S will be able to sustain or increase its dividend.Read more about Coloplast A/S's dividend. News and Social Media3.1 / 5News SentimentN/A News SentimentColoplast A/S has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Coloplast A/S this week, compared to 0 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coloplast A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsColoplast A/S has minimal institutional ownership at this time.Read more about Coloplast A/S's insider trading history. Receive CLPBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coloplast A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLPBY Stock News HeadlinesCritical Comparison: Treace Medical Concepts (NASDAQ:TMCI) and Coloplast A/S (OTCMKTS:CLPBY)November 7, 2026 | americanbankingnews.comAnalyzing Omnicell (NASDAQ:OMCL) and Coloplast A/S (OTCMKTS:CLPBY)November 6, 2026 | americanbankingnews.comA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.November 16 at 1:00 AM | Profits Run (Ad)Coloplast A/S (CLPBY) Q4 2026 Earnings Call TranscriptNovember 3, 2026 | seekingalpha.comColoplast pares back China operations as market recovery remains elusiveNovember 3, 2026 | reuters.comColoplast A/S - FY 2025/26 Earnings Release - Invitation for conference call on 3 November 2026 at 11.00am CETOctober 21, 2026 | marketscreener.comMCLPBY Share News TodayJune 22, 2026 | uk.investing.comColoplast's Next Generation Inflatable Penile Prosthesis Approved by the FDA – can help millions of menJune 3, 2026 | globenewswire.comSee More Headlines CLPBY Stock Analysis - Frequently Asked Questions How have CLPBY shares performed this year? Coloplast A/S's stock was trading at $8.50 on January 1st, 2026. Since then, CLPBY stock has decreased by 12.2% and is now trading at $7.46. How were Coloplast A/S's earnings last quarter? Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) announced its quarterly earnings results on Tuesday, November, 3rd. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.00. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. Coloplast A/S had a trailing twelve-month return on equity of 42.25% and a net margin of 10.57%. How do I buy shares of Coloplast A/S? Shares of CLPBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coloplast A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coloplast A/S investors own include Advanced Micro Devices (AMD), ASML (ASML), Broadcom (AVGO), GDS (GDS), Citigroup (C), Delta Air Lines (DAL) and GE Aerospace (GE). Company Calendar Last Earnings11/03/2026Today11/16/2026Fiscal Year End9/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolOTCMKTS:CLPBY Previous SymbolNASDAQ:CLPBY CIK1294325 Webwww.coloplast.com Phone(454) 911-1111FaxN/AEmployees17,156Year Founded1957Profitability EPS (Trailing Twelve Months)$0.21 Trailing P/E Ratio18.67 Forward P/E Ratio18.20 P/E Growth3.54Net Income$478.04 million Net Margins10.57% Pretax Margin13.97% Return on Equity42.25% Return on Assets11.87% Debt Debt-to-Equity Ratio1.51 Current Ratio1.56 Quick Ratio0.94 Sales & Book Value Annual Sales$4.50 billion Price / Sales3.74 Cash Flow$0.37 per share Price / Cash Flow20.30 Book Value$1.06 per share Price / Book7.04Miscellaneous Outstanding Shares2,253,670,000Free FloatN/AMarket Cap$16.81 billion OptionableNot Optionable Beta0.10 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (OTCMKTS:CLPBY) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredSmall-Cap SMX is Taking its Technology into Multiple Trillion-Dollar Industries!SMX (NASDAQ: SMX) uses proprietary molecular-marking technology and a Digital Material Passport platform to gi...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coloplast A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Coloplast A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.